Results 261 to 270 of about 148,910 (315)
Canadian family physician Medecin de famille canadien, 1978 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Endocrinology and Metabolism Clinics of North America, 1997
Metformin, a dimethylbiguanide, was first synthesized in 1929 and was shown to be a potent hypoglycemic agent. It was rediscovered in 1957 and was widely used in Europe to treat obese type II patients. Metformin resurfaced in the 1980s and was shown to increase insulin sensitivity; this has led to its introduction to clinical practice in the United ...
P M, Bell, D R, Hadden
openaire +2 more sources
Metformin, a dimethylbiguanide, was first synthesized in 1929 and was shown to be a potent hypoglycemic agent. It was rediscovered in 1957 and was widely used in Europe to treat obese type II patients. Metformin resurfaced in the 1980s and was shown to increase insulin sensitivity; this has led to its introduction to clinical practice in the United ...
P M, Bell, D R, Hadden
openaire +2 more sources
Current Diabetes Reviews, 2020
Introduction: The Diabetes Prevention Program study results indicated that metformin therapy was not as beneficial as a lifestyle modification for delaying the development of type 2 diabetes in individuals at high risk of the disease. A key feature in the etiology of type 2 diabetes mellitus, which appears in the prediabetic phase, is a significant ...
Rob N M, Weijers, Dick J, Bekedam
openaire +2 more sources
Introduction: The Diabetes Prevention Program study results indicated that metformin therapy was not as beneficial as a lifestyle modification for delaying the development of type 2 diabetes in individuals at high risk of the disease. A key feature in the etiology of type 2 diabetes mellitus, which appears in the prediabetic phase, is a significant ...
Rob N M, Weijers, Dick J, Bekedam
openaire +2 more sources
Drugs of Today, 2008
Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today. Despite low potency and a long list of contraindications, metformin has remained successful and even expanded experimental use due to its ...
openaire +2 more sources
Metformin is a well-established ingredient of diabetes management, both as a monotherapy in early stages of type 2 diabetes and as adjunct therapy to virtually every other antihyperglycemic medicine available today. Despite low potency and a long list of contraindications, metformin has remained successful and even expanded experimental use due to its ...
openaire +2 more sources
European Journal of Emergency Medicine, 2009
info:eu-repo/semantics ...
Lheureux, Philippe +2 more
openaire +2 more sources
info:eu-repo/semantics ...
Lheureux, Philippe +2 more
openaire +2 more sources
Drugs, 2006
A fixed-dose pioglitazone/metformin tablet is approved in the US and the EU for the treatment of adult patients with type 2 diabetes mellitus who currently have inadequate glycaemic control with metformin monotherapy. In the US, the combination tablet is also approved for the treatment of adult patients with type 2 diabetes who currently have ...
Emma D, Deeks, Lesley J, Scott
openaire +2 more sources
A fixed-dose pioglitazone/metformin tablet is approved in the US and the EU for the treatment of adult patients with type 2 diabetes mellitus who currently have inadequate glycaemic control with metformin monotherapy. In the US, the combination tablet is also approved for the treatment of adult patients with type 2 diabetes who currently have ...
Emma D, Deeks, Lesley J, Scott
openaire +2 more sources
General Pharmacology: The Vascular System, 1993
Metformin (dimethylbiguanide) is an antihyperglycaemic drug used to treat non-insulin dependent diabetes mellitus. It acts in the presence of insulin to increase glucose utilization and reduce glucose production, thereby countering insulin resistance.
openaire +2 more sources
Metformin (dimethylbiguanide) is an antihyperglycaemic drug used to treat non-insulin dependent diabetes mellitus. It acts in the presence of insulin to increase glucose utilization and reduce glucose production, thereby countering insulin resistance.
openaire +2 more sources